Skip to main content
SpringerLink
Log in

Medical therapy of acromegaly in Turkey

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Acromegaly is associated with multiple comorbidities and risk of premature mortality. Mortality rate of acromegalic patients is similar to that of the general population when normal GH levels are achieved. Surgery is the mainstay of acromegaly but when surgery fails to achieve disease control, or when surgery is impossible or contraindicated, patients are offered medical therapy and/or radiotherapy. Current medical therapy modalities were revised in this short review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102–52.

    Article  PubMed  CAS  Google Scholar 

  2. Gullu BE, Celik O, Gazioglu N, Kadioglu P. Thyroid cancer is the most common cancer associated with acromegaly. Pituitary 2010, 13: 242–8.

    Article  PubMed  Google Scholar 

  3. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83: 2730–4.

    PubMed  CAS  Google Scholar 

  4. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85: 526–9.

    PubMed  CAS  Google Scholar 

  5. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009, 94: 1509–17.

    Article  PubMed  CAS  Google Scholar 

  6. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients of acromegaly using current criteria of biochemical “cure”. Eur J Endocrinol 2005, 152: 379–87.

    Article  PubMed  CAS  Google Scholar 

  7. Barkan A, Bronstein MD, Bruno OD, et al. Management of acromegaly in Latin America: expert panel recommendations. Pituitary 2010, 13: 168–75.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Erturk E, Tuncel E, Kiyici S, Ersoy C, Duran C, Imamoglu S. Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience. Pituitary 2005, 8: 93–7.

    Article  PubMed  Google Scholar 

  9. Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest 2009, 119: 3189–200.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  10. Bush ZM, Vance ML. Management of acromegaly: is there a role for primary medical therapy? Rev Endocr metab Disord 2008, 9: 83–94.

    Article  PubMed  Google Scholar 

  11. Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 2008, 286: 192–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  12. Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G. Benefical effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007, 157: 579–87.

    Article  PubMed  CAS  Google Scholar 

  13. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomized controlled trial. Eur J Endocrinol 2009, 161: 331–8.

    Article  PubMed  CAS  Google Scholar 

  14. Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodinamic analysis of lanreotide Autogel. Metabolism 2005, 54: 1276–81.

    Article  PubMed  CAS  Google Scholar 

  15. Fløgstad AK, Halse J, Bakke S, Lancranjan I, Marbach P, Bruns C, Jervell J. Sandostatin LAR in acromegalic patients: long-term treatment. J Clin Endocrinol Metab 1997, 82: 23–8.

    Article  PubMed  Google Scholar 

  16. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90: 4465–73.

    Article  PubMed  CAS  Google Scholar 

  17. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 2008, 93: 2957–68.

    Article  PubMed  CAS  Google Scholar 

  18. Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide micopaticles 30 mg: a phase III trial. Clin Endocrinol (Oxf) 2006, 65: 320–6.

    Article  CAS  Google Scholar 

  19. Van Thiel SW, Romijn JA, Biermasz NR, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 2004, 150: 489–95.

    Article  PubMed  Google Scholar 

  20. Alexopoulou O, Abrams P, Verhelst J, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004, 151: 317–24.

    Article  PubMed  CAS  Google Scholar 

  21. Ashwell SG, Bevan JS, Edwards OM, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 2004, 150: 473–80.

    Article  PubMed  CAS  Google Scholar 

  22. Ronchi CL, Boschetti M, Degli Uberti EC, et al; Italian Multicenter Autogel Study Group in Acromegaly. Efficacy of a slow-release formulation of lanreotide(Autogel)120mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf) 2007, 67: 512–9.

    CAS  Google Scholar 

  23. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly. Clin Endocrinol (Oxf) 2008, 68: 473–80.

    Article  CAS  Google Scholar 

  24. Yetkin DO, Boysan SN, Tiryakioglu O, Yalin AS, Kadioglu P. Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long-acting somatostatin analog octreotide. Endocrinol J 2007, 54: 459–64.

    CAS  Google Scholar 

  25. Ronchi CL, Orsi E, Giavoli C, et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest 2003, 26: 533–8.

    Article  PubMed  CAS  Google Scholar 

  26. Ertorer ME, Bakıner O, Anaforoglu I, Bozkırlı E, Tütüncü NB, Demirag NG. Lanreotide autogel and insulin sensitivity markers: report of 5 acromegalic patients and literature review. Neuro Endocrinol Lett 2007, 28: 727–33.

    PubMed  CAS  Google Scholar 

  27. Colao A, Pivonello R, Auriemma RS, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006, 91: 2112–8.

    Article  PubMed  CAS  Google Scholar 

  28. Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010, 13: 60–7.

    Article  PubMed  CAS  Google Scholar 

  29. Colao A, Ferone D, Cappabianca P, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 1997 82: 3308–14.

    Article  PubMed  CAS  Google Scholar 

  30. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignanó T, Giovanelli M. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 2006, 104: 899–906.

    Article  PubMed  CAS  Google Scholar 

  31. Carlsen SM, Lund-Johansen M, Schreiner T, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective randomized trial. J Clin Endocrinol Metab 2008, 93: 2984–90.

    Article  PubMed  CAS  Google Scholar 

  32. Bevan JS, Atkin SL, Atkinson AB, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow release octreotide on growth hormone, insulin like growth factor-I, and tumor size. J Clin Endocrinol Metab 2002, 87: 4554–63.

    Article  PubMed  CAS  Google Scholar 

  33. Mercado M, Borges F, Bouterfa H, et al; SMS995B2401 Study Group. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 2007, 66: 859–906.

    Article  CAS  Google Scholar 

  34. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001, 86: 2779–86.

    PubMed  CAS  Google Scholar 

  35. Ozbek M, Erdogan M, Gönülalan G. Disappearence of a GH secreting macroadenoma, during long term somatostatin analogue administration. Exp Clin Endocrinol Diabetes 2009, 117: 309–11.

    Article  PubMed  CAS  Google Scholar 

  36. Kumar SS, Ayuk J, Murray RD. Current therapy and drug pipeline for the treatment of patients with acromegaly. Adv Ther 2009, 26: 383–403.

    Article  PubMed  CAS  Google Scholar 

  37. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary shrinkage. Endocr Rev 1992, 13: 221–35.

    Article  Google Scholar 

  38. Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998, 83: 374–8.

    Article  PubMed  CAS  Google Scholar 

  39. Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: benefical effects of cabergoline in patients uncontrolled with long acting release octreotide. Neuroendocrinology 2009, 90: 82–92.

    Article  PubMed  CAS  Google Scholar 

  40. Hodish I, Barkan A. Long-term effects of pegvisomantin patients with acromegaly. Nature Clin Pract Endocrinol Metab 2008, 4: 324–32.

    CAS  Google Scholar 

  41. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone receptor antagonist pegvisomant. New Engl J Med 2000, 342: 1171–7.

    Article  PubMed  CAS  Google Scholar 

  42. Buchfelder M, Schlaffer S, Droste M, et al; German Pegvisomant Observational Study. The German ACROSTUDY: past and present. Eur J Endocrinol 2009, 161: 3–10.

    Article  CAS  Google Scholar 

  43. Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005, 365: 1644–6.

    Article  PubMed  CAS  Google Scholar 

  44. Higham CE, Thomas JD, Bidlingmaier M, Drake WM, Trainer PJ. Successful use of weekly pegvisomant administration in patients with acromegaly. Eur J Endocrinol 2009, 161: 21–5.

    Article  PubMed  CAS  Google Scholar 

  45. Neggers SJCMM, de Herder WW, Janssen JAMJL, Feelders RA, van der Lely AJ. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 2009, 160: 529–33.

    Article  PubMed  CAS  Google Scholar 

  46. Higham CE, Chung TT, Lawrance J, Drake WM, Trainer PJ. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol (Oxf) 2009, 71: 86–91.

    Article  CAS  Google Scholar 

  47. van der Hoek J, de Herder WW, Feelders RA, et al. Asingle-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004, 89: 638–45.

    Article  PubMed  CAS  Google Scholar 

  48. Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) Demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010, 95: 2781–9.

    Article  PubMed  CAS  Google Scholar 

  49. Bastemir M, Akin F, Yaylali GF. The PPAR-gamma activator rosiglitazone fails to lower plasma growth hormone and insulin-like growth factor-1 levels in patients with acromegaly. Neuroendocrinology 2007, 86: 119–23.

    Article  PubMed  CAS  Google Scholar 

  50. Biermasz NR, Romijn JA, Pereira AM, Roelfsema F. Current pharmacotherapy for acromegaly: a review. Expert Opin Pharmacother 2005, 6: 2393–405.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical School, University of Istanbul, Istanbul, Turkey

    O. Celik & P. Kadioglu MD

Authors
  1. O. Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Kadioglu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Kadioglu MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Celik, O., Kadioglu, P. Medical therapy of acromegaly in Turkey. J Endocrinol Invest 33, 592–598 (2010). https://doi.org/10.1007/BF03346654

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346654

Key-words

Search

Navigation